Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease, affecting more than ...

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease, affecting more than 10 million people ...

Findings revealed biological pathways as potential intervention points, and demonstrated in fruit flies potential therapeutic strategies.

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...

As we age, we begin to lose the connections that wire up our brains-and neuroscientists aren't sure why. It is increasingly clear, though, that the loss of synapses-the flexible and adaptive relay ...

As we age, we begin to lose the connections that wire up our brains-and neuroscientists aren't sure why.

Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced ...

Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...

Zinc and vitamin A together can produce a synergistic effect to improve vision, immunity and other vital functions.

Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidel ...